{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:08:16Z","timestamp":1761718096751},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,5,29]],"date-time":"2009-05-29T00:00:00Z","timestamp":1243555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00345-009-0429-6","type":"journal-article","created":{"date-parts":[[2009,5,28]],"date-time":"2009-05-28T06:56:22Z","timestamp":1243493782000},"page":"343-346","source":"Crossref","is-referenced-by-count":13,"title":["Combination of BCG and interferon intravesical immunotherapy: an update"],"prefix":"10.1007","volume":"27","author":[{"given":"Kenneth G.","family":"Nepple","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard A.","family":"Aubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Braasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,29]]},"reference":[{"key":"429_CR1","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","volume":"178","author":"MC Hall","year":"2007","unstructured":"Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314\u20132330. doi: 10.1016\/j.juro.2007.09.003","journal-title":"J Urol"},{"key":"429_CR2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:180\u2013183","journal-title":"J Urol"},{"key":"429_CR3","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","volume":"325","author":"DL Lamm","year":"1991","unstructured":"Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF et al (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacilli Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325:1205\u20131209","journal-title":"N Engl J Med"},{"key":"429_CR4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0022-5347(17)55150-2","volume":"125","author":"A Morales","year":"1981","unstructured":"Morales A, Ottenhof P, Emerson L (1981) Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin. J Urol 125:649\u2013651","journal-title":"J Urol"},{"key":"429_CR5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","volume":"24","author":"MA O\u2019Donnell","year":"2006","unstructured":"O\u2019Donnell MA, Bohle A (2006) Treatment options for BCG failures. World J Urol 24:481\u2013487. doi: 10.1007\/s00345-006-0112-0","journal-title":"World J Urol"},{"key":"429_CR6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","volume":"44","author":"AP Meijden van der","year":"2003","unstructured":"van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV, EORTC Genito-Urinary Tract Cancer Group (2003) Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44:429\u2013434. doi: 10.1016\/S0302-2838(03)00357-9","journal-title":"Eur Urol"},{"key":"429_CR7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","volume":"152","author":"RB Nadler","year":"1994","unstructured":"Nadler RB, Catalona WJ, Hudson MA, Ratliff TL (1994) Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 152:367\u2013373","journal-title":"J Urol"},{"key":"429_CR8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00042307-200409000-00005","volume":"14","author":"FN Joudi","year":"2004","unstructured":"Joudi FN, O\u2019Donnell MA (2004) Second-line intravesical therapy versus cystectomy for bacilli Calmette-Guerin failures. Curr Opin Urol 14:271\u2013275. doi: 10.1097\/00042307-200409000-00005","journal-title":"Curr Opin Urol"},{"key":"429_CR9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.urolonc.2007.11.031","volume":"26","author":"MP Simons","year":"2008","unstructured":"Simons MP, O\u2019Donnell MA, Griffith TS (2008) Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol 26:341\u2013345. doi: 10.1016\/j.urolonc.2007.11.031","journal-title":"Urol Oncol"},{"key":"429_CR10","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","volume":"162","author":"Y Luo","year":"1999","unstructured":"Luo Y, Chen X, Downs TM, DeWolf WC, O\u2019Donnell MA (1999) IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Gu\u00e9rin immunotherapy. J Immunol 162:2399\u20132405","journal-title":"J Immunol"},{"key":"429_CR11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1084\/jem.189.9.1451","volume":"189","author":"N Kayagaki","year":"1999","unstructured":"Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H (1999) Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 189:1451\u20131460. doi: 10.1084\/jem.189.9.1451","journal-title":"J Exp Med"},{"key":"429_CR12","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1084\/jem.190.8.1155","volume":"190","author":"NA Fanger","year":"1999","unstructured":"Fanger NA, Maliszewski CR, Schooley K, Griffith TS (1999) Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190:1155\u20131164. doi: 10.1084\/jem.190.8.1155","journal-title":"J Exp Med"},{"key":"429_CR13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01517219","volume":"41","author":"K Pryor","year":"1995","unstructured":"Pryor K, Stricker P, Russell P, Golovsky D, Penny R (1995) Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro. Cancer Immunol Immunother 41:309\u2013316. doi: 10.1007\/BF01517219","journal-title":"Cancer Immunol Immunother"},{"key":"429_CR14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","volume":"89","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"2002","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA, Flores N, Isorna S, Solsona E, Sebasti\u00e1n JL, Pertusa C, Rioja LA, Mart\u00ednez-Pi\u00f1eiro L et al (2002) Long-term follow-up of a randomized prospective trial comparing a standard 81\u00a0mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27\u00a0mg in superficial bladder cancer. BJU Int 89:671\u2013680. doi: 10.1046\/j.1464-410X.2002.02722.x","journal-title":"BJU Int"},{"key":"429_CR15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","volume":"24","author":"FN Joudi","year":"2006","unstructured":"Joudi FN, Smith BJ, O\u2019Donnell MA, National BCG-Interferon Phase 2 Investigator Group (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24:344\u2013348. doi: 10.1016\/j.urolonc.2005.11.026","journal-title":"Urol Oncol"},{"key":"429_CR16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666\u2013675","journal-title":"J Clin Oncol"},{"key":"429_CR17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0094-0143(05)70245-7","volume":"27","author":"DH Brown","year":"2000","unstructured":"Brown DH, Wagner TT, Bahnson RR (2000) Interferons and bladder cancer. Urol Clin North Am 27:171\u2013178. doi: 10.1016\/S0094-0143(05)70245-7","journal-title":"Urol Clin North Am"},{"key":"429_CR18","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","volume":"166","author":"MA O\u2019Donnell","year":"2001","unstructured":"O\u2019Donnell MA, Krohn J, DeWolf WC (2001) Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 166:1300\u20131304. doi: 10.1016\/S0022-5347(05)65757-6","journal-title":"J Urol"},{"key":"429_CR19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1078-1439(03)00012-7","volume":"21","author":"JS Lam","year":"2003","unstructured":"Lam JS, Benson MC, O\u2019Donnell MA, Sawczuk A, Gavazzi A, Weschler MH, Sawczuk IS (2003) Bacillus Calmete-Gu\u00e9rin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21:354\u2013360. doi: 10.1016\/S1078-1439(03)00012-7","journal-title":"Urol Oncol"},{"key":"429_CR20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0090-4295(01)01187-6","volume":"58","author":"LG Luciani","year":"2001","unstructured":"Luciani LG, Neulander E, Murphy WM, Wajsman Z (2001) Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology 58:376\u2013379. doi: 10.1016\/S0090-4295(01)01187-6","journal-title":"Urology"},{"key":"429_CR21","first-page":"1790","volume":"10","author":"SP Punnen","year":"2003","unstructured":"Punnen SP, Chin JL, Jewett MA (2003) Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can J Urol 10:1790\u20131795","journal-title":"Can J Urol"},{"key":"429_CR22","first-page":"3189","volume":"13","author":"PI Karakiewicz","year":"2006","unstructured":"Karakiewicz PI, Benayoun S, Lewinshtein DJ, Chun FK, Shahrour K, Perrotte P (2006) Treatment of BCG failures with intravesical BCG\/Interferon: the University of Montreal experience. Can J Urol 13:3189\u20133194","journal-title":"Can J Urol"},{"key":"429_CR23","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","volume":"175","author":"FN Joudi","year":"2006","unstructured":"Joudi FN, Smith BJ, O\u2019Donnell MA, Konety BR (2006) The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 175:1634\u20131640. doi: 10.1016\/S0022-5347(05)00973-0","journal-title":"J Urol"},{"key":"429_CR24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","volume":"71","author":"BL Gallagher","year":"2008","unstructured":"Gallagher BL, Joudi FN, Maym\u00ed JL, O\u2019Donnell MA (2008) Impact of previous bacille Calmette-Gu\u00e9rin failure pattern on subsequent response to bacille Calmette-Gu\u00e9rin plus interferon intravesical therapy. Urology 71:297\u2013301. doi: 10.1016\/j.urology.2007.09.050","journal-title":"Urology"},{"key":"429_CR25","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-5347(17)39547-2","volume":"144","author":"RW Glashan","year":"1990","unstructured":"Glashan RW (1990) A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 144:658\u2013661","journal-title":"J Urol"},{"key":"429_CR26","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0022-5347(01)63160-4","volume":"159","author":"AS Belldegrun","year":"1998","unstructured":"Belldegrun AS, Franklin JR, O\u2019Donnell MA, Gomella LG, Klein E, Neri R, Nseyo UO, Ratliff TL et al (1998) Superficial bladder cancer: the role of interferon-alpha. J Urol 159:1793\u20131801. doi: 10.1016\/S0022-5347(01)63160-4","journal-title":"J Urol"},{"issue":"4 Suppl","key":"429_CR27","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0022-5347(08)61713-9","volume":"179","author":"DL Lamm","year":"2008","unstructured":"Lamm DL, O\u2019Donnell MA (2008) Multicenter randomized comparison of BCG with or without alfa 2b interferon (IFN) and Oncovite (Onc) versus recommended daily allowance (RDA) vitamins during induction and extended 3-week maintenance. J Urol 179(4 Suppl):584 (abstract no. 1705)","journal-title":"J Urol"},{"issue":"4 Suppl","key":"429_CR28","first-page":"152","volume":"164","author":"K Esuvaranathan","year":"2000","unstructured":"Esuvaranathan K, Kamaraj R, Mohan RS et al (2000) A phase IIB trial of BCG combined with interferon alpha for bladder cancer. J Urol 164(4 Suppl):152 (abstract no. 675)","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-009-0429-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-009-0429-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-009-0429-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T10:21:26Z","timestamp":1685010086000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-009-0429-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,29]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1007\/s00345-009-0429-6","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,29]]}}}